Webb10 jan. 2024 · Triple-negative breast cancer (TNBC) is characterized by the absence of hormone receptor and HER2 expression, and therefore a lack of therapeutic targets. Anthracyclines and taxane-based neoadjuvant chemotherapy have historically been the cornerstone of treatment of early TNBC. Webb12 apr. 2024 · Higher TIL density in pretreatment breast cancer biopsies is also associated with a better response to neoadjuvant chemotherapy 2 and improved DFS and OS in patients with node-positive TNBC 38 ...
Neoadjuvant therapy for triple-negative breast cancer: potential ...
Webb13 maj 2024 · In addition, in a cohort of 20 patients with germline BRCA mutations (15 with TNBC), 6 months of neoadjuvant talazoparib for patients with operable TNBC resulted in a residual cancer burden-0 rate of 53%. 22 Two important limitations of combining a PARP inhibitor with chemotherapy exist. Webb1 juli 2024 · BackgroundTriple-negative breast cancer (TNBC) comprises 15% of invasive breast cancers. Platinum-based chemotherapy and immune checkpoint inhibitors (ICIs) have been extensively researched in recent years as promising treatments in the neoadjuvant setting. However, clinical data is lacking in direct comparisons of these two … boat hire sydney nsw
Treatment landscape of triple-negative breast cancer - Nature
WebbOn July 26, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination … Webb15 juni 2024 · The survival outcomes of neoadjuvant chemotherapy (NACT) versus adjuvant chemotherapy (ACT) for patients with triple-negative breast cancer (TNBC) … WebbTriple-negative breast cancer (TNBC) is a heterogeneous disease with varying responses to neoadjuvant chemotherapy (NAC). The identification of biomarkers to predict NAC … boat hire taunton